In this study, 296 patients with metastatic ALK-fusion-positive NSCLC were randomized to receive lorlatinib (n = 149) or crizotinib (n = 147), with PFS as the primary endpoint. This evidence concerns the gene ALK and non-small cell lung carcinoma.